Literature DB >> 23190286

Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine.

S Svalheim1, U Mushtaq, M Mochol, G Luef, M Rauchenzauner, S S Frøland, E Taubøll.   

Abstract

OBJECTIVES: The aim of the study was to investigate immunoglobulin levels in patients with epilepsy using the antiepileptic drugs (AED) levetiracetam (LEV), carbamazepine (CBZ), or lamotrigine (LTG).
METHODS: A total of 211 patients and 80 controls (age: 18-45 years) of both genders were included. The patients had been treated with either LEV (n = 47), CBZ (n = 90), or LTG (n = 74) monotherapy for at least 6 months. Total concentrations of immunoglobulin G (IgG), IgG subclasses (IgG1, IgG2, IgG3, and IgG4), immunoglobulin A (IgA), and immunoglobulin M (IgM) were measured. Smoking, drinking habits, and physical activity were recorded, and body mass index (BMI) was calculated.
RESULTS: A significantly lower total IgG and IgG1 was found in both men and women treated with LTG and in men on CBZ. IgG2 and IgG4 were also lower in LTG-treated women, and IgA and IgM were lower in LTG-treated men. Patients treated with LEV did not differ from the control group.
CONCLUSIONS: Low levels of immunoglobulins were found in patients with epilepsy treated with LTG or CBZ. As our group of patients consisted of otherwise healthy young adults, one should be especially aware of a possible effect of AEDs on immunoglobulin levels when treating selected patient groups, for example immunocompromised patients. Immunoglobulin concentrations should be measured in patients treated with LTG or CBZ who experience recurrent infections, and a change in medication should be considered.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23190286     DOI: 10.1111/ane.12044

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  3 in total

1.  B cell aplasia and hypogammaglobulinemia associated with levetiracetam.

Authors:  Hulya Ozdemir; Sua Sumer; Hakan Karabagli; Gokhan Akdemir; A Zafer Caliskaner; Hasibe Artac
Journal:  Ann Saudi Med       Date:  2018-01-09       Impact factor: 1.526

Review 2.  Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.

Authors:  Hans-Hartmut Peter; Hans D Ochs; Charlotte Cunningham-Rundles; Donald C Vinh; Peter Kiessling; Bernhard Greve; Stephen Jolles
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793

3.  Tonsillar granuloma associated with hypogammaglobulinemia.

Authors:  Aleksi Laajala; Outi Kuismin; Mikko Tastula; Leena Tiitto; Saila Kauppila; Anna Salo; Pirjo Åström; Antti Nissinen; Virpi Glumoff; Mikko R J Seppänen; Timo Hautala
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-29       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.